EBT-101
HIV-1 Infection
Phase 1/2Active
Key Facts
About Excision BioTherapeutics
Excision BioTherapeutics is pioneering the application of CRISPR gene-editing technology to directly target and eliminate latent viral DNA from the human genome, focusing on large and complex viruses like HIV, HSV, and HBV. The company's lead program, EBT-101, is a first-in-human CRISPR-based therapy for HIV that has completed a Phase 1/2 trial, demonstrating initial safety and proof-of-concept. As a private, pre-revenue entity, Excision is advancing a pipeline of in vivo gene therapies with the potential to address significant unmet medical needs in virology and genetic diseases. Its strategy combines a novel therapeutic approach with a platform capable of targeting multiple indications.
View full company profileTherapeutic Areas
Other HIV-1 Infection Drugs
| Drug | Company | Phase |
|---|---|---|
| Lenacapavir | Dr. Reddy's Laboratories | Approved |
| Elpida® (elsulfavirine) Daily Oral | Viriom | Approved |
| Agape® FDC | Viriom | Approved |
| Depulfavirine Injectable (DPV) | Viriom | Approved |
| Elsulfavirine FDCs (w/ NRTI/INSTI) | Viriom | Bioequivalence |
| VM3500 LA Injectable | Viriom | Pre-clinical |